AltMountain

Prosight Capital

Dallas, TX · CRD 148791
Hedge fund manager

Prosight Capital is an SEC-registered investment adviser based in Dallas, TX that reports managing 2 hedge funds on Form ADV. It reports $1.0 billion in regulatory assets under management. Its private funds, of all types, hold $277.6 million in gross assets. Its disclosed U.S. stock holdings returned an estimated -1.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +26.7% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$1.0 billionForm ADV Item 5.F
Gross assets of private funds
$277.6 millionAll private fund types, Form ADV
Hedge funds managed
22 private funds in total
Employees
5Form ADV Item 5.A
Registration
SEC-registered adviserCRD 148791
Latest Form ADV
03/30/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD-1.1%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+26.7%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$580.4 million36 positions, 2026-06-30
$85$111$137Q3 2024Q1 2025Q3 2025Q1 202613F est. $127S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+2.4%+14.8%
Q1 2026-3.4%-4.6%
Q4 2025+12.2%+2.4%
Q3 2025+27.2%+7.8%
Q2 2025+5.6%+10.4%
Q1 2025-13.6%-4.5%
Q4 2024-6.2%+2.1%
Q3 2024+5.0%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 32 share positions ($515,482,740) reported by Prosight Management, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Lakefront Biotherapeutics NV11.49%
  • Shattuck Labs Inc10.12%
  • Janux Therapeutics Inc9.87%
  • Nektar Therapeutics9.22%
  • Abivax SA7.24%
  • Insmed Inc5.27%
  • Boston Scientific Corp4.66%
  • Irhythm Holdings Inc4.43%
  • Alkermes PLC4.32%
  • Privia Health Group Inc4.01%
StockValue% of 13F portfolioSharesShares vs prior quarter
Lakefront Biotherapeutics NV$59,252,56011.49%1,998,400-2.20%
Shattuck Labs Inc$52,160,00110.12%7,648,094+28.37%
Janux Therapeutics Inc$50,858,4969.87%2,943,200-22.64%
Nektar Therapeutics$47,527,8259.22%785,000-3.09%
Abivax SA$37,310,1427.24%376,794+250.85%
Insmed Inc$27,175,3645.27%238,088-36.61%
Boston Scientific Corp$24,007,5004.66%550,000-56.70%
Irhythm Holdings Inc$22,843,3874.43%200,980+21.44%
Alkermes PLC$22,286,0004.32%550,000+39.46%
Privia Health Group Inc$20,669,6174.01%1,049,752New
Mineralys Therapeutics Inc$20,104,0003.90%800,000+77.86%
Zymeworks Inc$19,101,9393.71%721,100+6.92%
Syndax Pharmaceuticals Inc$15,276,5422.96%812,582-32.28%
Kura Oncology Inc$13,655,2502.65%1,275,000-36.94%
Denali Therapeutics Inc$11,382,9692.21%550,700New
Praxis Precision Medicines I$10,600,7722.06%36,400New
Healthequity Inc$10,243,3141.99%115,796New
Bridgebio Pharma Inc$9,870,0001.91%150,000New
Alnylam Pharmaceuticals Inc$9,129,3801.77%37,000-62.28%
Humana Inc$8,394,5401.63%22,000New
Enovis Corporation$4,885,9830.95%267,432New
Onkure Therapeutics Inc$3,612,1780.70%1,325,570-9.73%
Quanterix Corp$3,060,7500.59%825,000New
Generate Biomedicines Inc$2,174,2350.42%144,756New
An2 Therapeutics Inc$1,866,6660.36%350,877-26.07%
Pliant Therapeutics Inc$1,732,8230.34%1,604,466+17.09%
Rocket Pharmaceuticals Inc$1,564,9130.30%595,024-15.00%
Rein Therapeutics Inc$1,334,7980.26%1,660,197+50.93%
Coya Therapeutics Inc$1,150,2960.22%229,600+35.06%
Corbus Pharmaceuticals Hldgs$1,148,3720.22%168,383-74.09%
Immuneering Corp$614,2500.12%150,000+306.93%
Adc Therapeutics SA$487,8780.09%399,900-94.89%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 9 new positions, 13 sold out, 10 increased, 13 reduced and 0 unchanged.

Number of positions (a count, not dollars)

  • New positions9
  • Increased10
  • Unchanged0
  • Reduced13
  • Sold out13

New positions

StockValueShares
Privia Health Group Inc$20,669,6171,049,752
Denali Therapeutics Inc$11,382,969550,700
Praxis Precision Medicines I$10,600,77236,400
Healthequity Inc$10,243,314115,796
Bridgebio Pharma Inc$9,870,000150,000
Humana Inc$8,394,54022,000
Enovis Corporation$4,885,983267,432
Quanterix Corp$3,060,750825,000
Generate Biomedicines Inc$2,174,235144,756

Sold out

StockValue at Jun 30, 2026Shares held then
Veeva SYS Inc$18,847,314106,200
Crinetics Pharmaceuticals In$14,020,002374,666
Icu Med Inc$7,476,60051,000
Intuitive Surgical Inc$6,760,56017,000
Procept Biorobotics Corp$6,057,514268,269
Genedx Holdings Corp$5,869,57585,500
Option Care Health Inc$5,676,915270,716
Emergent Biosolutions Inc$3,854,398459,952
Pfizer Inc$3,259,613135,366
Orthopediatrics Corp$3,012,975157,500
Tectonic Therapeutic Inc$1,365,75339,731
Meiragtx Hldgs PLC$1,215,90090,000
Everforth Inc$1,206,22567,500

Largest increases

StockChange in sharesChangeValue nowShares now
Abivax SA+269,400+250.85%$37,310,142376,794
Shattuck Labs Inc+1,690,217+28.37%$52,160,0017,648,094
Mineralys Therapeutics Inc+350,205+77.86%$20,104,000800,000
Alkermes PLC+155,611+39.46%$22,286,000550,000
Irhythm Holdings Inc+35,480+21.44%$22,843,387200,980
Zymeworks Inc+46,666+6.92%$19,101,939721,100
Immuneering Corp+113,139+306.93%$614,250150,000
Rein Therapeutics Inc+560,197+50.93%$1,334,7981,660,197
Coya Therapeutics Inc+59,600+35.06%$1,150,296229,600
Pliant Therapeutics Inc+234,233+17.09%$1,732,8231,604,466

Largest reductions

StockChange in sharesChangeValue nowShares now
Boston Scientific Corp-720,273-56.70%$24,007,500550,000
Insmed Inc-137,521-36.61%$27,175,364238,088
Alnylam Pharmaceuticals Inc-61,080-62.28%$9,129,38037,000
Janux Therapeutics Inc-861,281-22.64%$50,858,4962,943,200
Adc Therapeutics SA-7,424,849-94.89%$487,878399,900
Kura Oncology Inc-746,964-36.94%$13,655,2501,275,000
Syndax Pharmaceuticals Inc-387,418-32.28%$15,276,542812,582
Corbus Pharmaceuticals Hldgs-481,617-74.09%$1,148,372168,383
Nektar Therapeutics-25,000-3.09%$47,527,825785,000
Lakefront Biotherapeutics NV-44,944-2.20%$59,252,5601,998,400
An2 Therapeutics Inc-123,761-26.07%$1,866,666350,877
Onkure Therapeutics Inc-142,918-9.73%$3,612,1781,325,570
Rocket Pharmaceuticals Inc-104,976-15.00%$1,564,913595,024

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Janux Therapeutics, Inc.13G amendment5.14%3,144,200Nov 13, 2026SEC.gov ↗
ADC Therapeutics SA13G amendment0.31%399,900Nov 13, 2026SEC.gov ↗
OnKure Therapeutics, Inc.13G amendment2.4%978,992Aug 10, 2026SEC.gov ↗
MeiraGTx Holdings plc13G amendment4%3,209,788Feb 13, 2026SEC.gov ↗
Mural Oncology plc13G amendment0%0Nov 13, 2025SEC.gov ↗
Shattuck Labs, Inc.13G amendment9.9%6,543,240Nov 13, 2025SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 13, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (2)

Fund
Gross assets
Minimum
Owners
Adviser
Prosight Plus Fund, LP
Delaware, United StatesHedge fund
Gross assets$179M
Minimum$1.0M
Owners10
AdviserProsight Capital
Prosight Fund, LP
Delaware, United StatesHedge fund
Gross assets$76.9M
Minimum$1.0M
Owners29
AdviserProsight Capital

As reported in the adviser's Form ADV filed Mar 27, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠